Nevro Corporation has announced a public offering of convertible senior notes. Due June 2021, the offering will raise gross proceeds of $125m. Nevro also granted the underwriters a 30-day option to purchase additional notes.

The global medical device company will use the proceeds from the offering to repay existing term loans, to fund note hedge transactions and for other general corporate purposes.

FluoroPharma Medical has collaborated with Sinotau USA to develop novel radiopharmaceutical approaches for improved care and outcomes in patients suffering from cardiovascular diseases.

Pursuant to the agreement, Sinotau will develop and commercialise FluoroPharma’s proprietary cardiac imaging assets CardioPET and BFPET in China and Canada. Once the products receive approval, the two companies will jointly conduct certain pre-market planning activities.

Transgenomic, a global biotechnology company, intends to raise $3.5m through a public placement of shares of its common stock. Gross proceeds from the offering will be utilised by the company for working capital and general corporate purposes.

“The companies have agreed to combine their healthcare applications to enable healthcare service providers to leverage connected devices and health data for personalised patient care.”

Royal Philips and Pegasystems have collaborated to enable improved patient-care through connected devices, cloud and analytics. The companies have agreed to combine their healthcare applications to enable healthcare service providers to leverage connected devices and health data for personalised patient care.

Pegasystems’ Pega Care Management Application will be combined with Philips’ Cloud platform, which provides connectivity to millions of connected health devices, to enable caregivers remotely manage care with connected health applications that can provide immediate access to a patient’s health status.

Wafergen Bio-systems has signed an exclusive distribution agreement with Takara Bio to distribute its single-cell and clinical research products in the Asia-Pacific region.

The agreement includes promotion and technical support of WaferGen’s ICELL8 Single-Cell System, SmartChip Real-Time PCR, SmartChip Target Enrichment and Apollo 324 products, in Japan.